Welcome to our dedicated page for Gh Research Plc SEC filings (Ticker: GHRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company focused on mebufotenin-based therapies for treatment-resistant depression and related psychiatric conditions. As a foreign private issuer, GH Research submits annual reports on Form 20-F and furnishes current information on Form 6-K.
In its Form 6-K current reports, the company provides updates on quarterly and interim financial results, business developments, and clinical progress. These filings often include condensed consolidated interim financial statements prepared under IFRS, detailing research and development expenses, general and administrative expenses, finance income and expense, and accumulated deficits typical of an R&D-focused enterprise. Balance sheet information in these filings outlines cash, cash equivalents, other financial assets, marketable securities, and equity components such as share capital and additional paid-in capital.
GH Research also uses Form 6-K to furnish press releases and investor materials describing milestones in its GH001 and GH002 programs, including Phase 2b and Phase 2a trial results, open-label extension data, safety and tolerability profiles, and regulatory interactions with the U.S. Food and Drug Administration. Additional 6-Ks announce participation in scientific congresses such as ECNP, ASCP, ISBD, and ACNP, where abstracts and presentations related to GH001-TRD-201 and other trials are shared.
Through this filings page, users can access GH Research’s SEC-submitted documents as they are made available from EDGAR. AI-powered tools on the platform can help summarize lengthy financial and clinical disclosures, highlight key points from interim results, and make it easier to track how GH Research’s development programs and capital position evolve across reporting periods.
GH Research PLC filed a report stating that it will participate in the 38th European College of Neuropsychopharmacology annual meeting, scheduled for October 11-14, 2025 in Amsterdam, the Netherlands. The company highlights this scientific and medical conference appearance through an attached press release, which is included as an exhibit.
The report notes that the press release is provided as of October 9, 2025 and clarifies that its availability should not be seen as an admission that the information is material. GH Research also states it does not undertake any obligation to update that press release or its forward-looking statements after that date.
GH Research PLC has filed an update stating that it will present data from its GH001-BD-202 clinical trial at the International Society for Bipolar Disorders Annual Meeting in Chiba, Japan, scheduled for September 17-19, 2025. The study evaluates inhaled mebufotenin (GH001) in patients with bipolar II disorder who are experiencing a current major depressive episode. A scientific poster titled “Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients with Bipolar II Disorder and a Current Major Depressive Episode”, to be presented by PD Dr. med. Philipp Ritter during Poster Session II, is attached as an exhibit. This filing mainly informs investors that detailed clinical data will be shared in a scientific forum and made available in the attached poster.
GH Research PLC filed an update stating it will participate in the Cantor Global Healthcare Conference in New York. The event is scheduled to take place from September 3-5, 2025, and the company plans to join a fireside chat and hold one-on-one meetings with investors. This type of participation is typically used to share the company’s story, engage with the investment community, and address investor questions in a conference setting.
RA Capital and related persons report a 12.4% stake in GH Research PLC as of June 30, 2025. The filing shows aggregate ownership of 7,676,697 Ordinary Shares out of 62,028,145 outstanding, based on the issuer's February 15, 2025 filing. The RA Capital Healthcare Fund directly holds 7,485,080 shares (12.1%) and RA Capital Nexus Fund II holds 191,617 shares. Reported holdings reflect shared voting and shared dispositive power only; sole voting and dispositive power are zero. The filing states RA Capital serves as investment adviser and has sole power to vote and dispose of the funds’ reported shares, while the funds disclaim beneficial ownership for purposes of Section 13(d) because they delegated those powers and may not revoke that delegation on less than 61 days’ notice.
Terwey Theis reports beneficial ownership of 4,692,903 ordinary shares of GH Research PLC, representing 7.6% of the outstanding class based on 62,029,395 shares outstanding as of June 30, 2025. The disclosure shows the reporting person is a German citizen and holds sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive arrangements.
This Schedule 13G amendment documents a substantial ownership position above the 5% threshold that requires public disclosure; it does not specify transactions, motives, or any arrangements with other holders.
GH Research PLC (NASDAQ: GHRS) filed a Form 6-K reporting that it has submitted a complete response to the U.S. FDA concerning the clinical hold on its Investigational New Drug (IND) application for GH001. The submission was made in June 2025 and disclosed to investors via a press release dated 20 June 2025 (attached as Exhibit 99.1).
The filing does not disclose FDA feedback, timelines, or whether the hold will be lifted. Management expressly states it will not update the press release or forward-looking statements, underscoring regulatory uncertainty. No financial statements, earnings metrics, or other operational updates accompany the filing.
Investor takeaway: The response filing is an incremental regulatory step that could enable clinical trials of GH001 to resume if the FDA is satisfied. However, material impact remains contingent on the FDA’s decision; therefore, the risk profile for GHRS is largely unchanged until further notice.
FAQ
What is the current stock price of Gh Research Plc (GHRS)?
What is the market cap of Gh Research Plc (GHRS)?
